These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24476011)

  • 41. Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes.
    Dioguardi Burgio M; Castera L; Oufighou M; Rautou PE; Paradis V; Bedossa P; Sartoris R; Ronot M; Bodard S; Garteiser P; Van Beers B; Valla D; Vilgrain V; Correas JM;
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1005-1013.e27. PubMed ID: 38072287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis.
    Jun BG; Park WY; Park EJ; Jang JY; Jeong SW; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Jin SY; Park S
    PLoS One; 2017; 12(8):e0182784. PubMed ID: 28813448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values.
    Galaski J; Schulz L; Krause J; Lohse AW
    Z Gastroenterol; 2018 Jan; 56(1):36-42. PubMed ID: 29316576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical research of fibroscan ‒ TE-CAP at noninvasive diagnosis of hepatic steatosis in children.
    Jia S; Zhou J; Zhang Q; Zhou S; Wang Z; Ye X; Wu J
    Clinics (Sao Paulo); 2024; 79():100387. PubMed ID: 38805982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis.
    Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Dal Bello B; Filice G; Filice C
    World J Gastroenterol; 2014 Jun; 20(21):6626-31. PubMed ID: 24914387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.
    Hsu PK; Wu LS; Su WW; Su PY; Chen YY; Hsu YC; Yen HH; Wu CL
    PLoS One; 2021; 16(10):e0254892. PubMed ID: 34653177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
    Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
    J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
    Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
    Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
    Wong VW; Petta S; Hiriart JB; Cammà C; Wong GL; Marra F; Vergniol J; Chan AW; Tuttolomondo A; Merrouche W; Chan HL; Le Bail B; Arena U; Craxì A; de Lédinghen V
    J Hepatol; 2017 Sep; 67(3):577-584. PubMed ID: 28506907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy.
    Tsochatzis EA; Gurusamy KS; Ntaoula S; Cholongitas E; Davidson BR; Burroughs AK
    J Hepatol; 2011 Apr; 54(4):650-9. PubMed ID: 21146892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.
    Wang Y; Fan Q; Wang T; Wen J; Wang H; Zhang T
    Int J Clin Exp Med; 2015; 8(10):17654-63. PubMed ID: 26770355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
    Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
    Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.
    Andrade P; Rodrigues S; Rodrigues-Pinto E; Gaspar R; Lopes J; Lopes S; Macedo G
    GE Port J Gastroenterol; 2017 Jul; 24(4):161-168. PubMed ID: 29255745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
    Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
    J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.
    Sasso M; Beaugrand M; de Ledinghen V; Douvin C; Marcellin P; Poupon R; Sandrin L; Miette V
    Ultrasound Med Biol; 2010 Nov; 36(11):1825-35. PubMed ID: 20870345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
    de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
    J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
    Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
    Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.
    Karlas T; Petroff D; Garnov N; Böhm S; Tenckhoff H; Wittekind C; Wiese M; Schiefke I; Linder N; Schaudinn A; Busse H; Kahn T; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2014; 9(3):e91987. PubMed ID: 24637477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study.
    Jiang M; Zhang X; Wu X; Xu Z; Pan J; He H; Luo Y; Chen J
    Ann Transl Med; 2023 Jan; 11(2):38. PubMed ID: 36819532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.